THC Therapeutics

THC Therapeutics is a publicly traded U.S. cannabis-focused holding company that has evolved from an earlier equipment business centered on the dHydronator cannabis and herb drying system into an acquirer and operator of legal cannabis assets. The company describes its strategy as building a diversified portfolio across cultivation, manufacturing, distribution, nutrients, genetics, and branded cannabis products. In 2025, THC Therapeutics announced acquisitions including The Headquarters Group and SugarTop Buddery, expanding its footprint in Oregon and California and increasing its exposure to vertically integrated cannabis operations. While it has been classified by some financial data providers under healthcare or specialty generic drug categories, the business is more accurately characterized as a regulated cannabis and wellness company rather than a traditional biotech or pharmaceutical developer. The company appears to have commercial-stage operating assets rather than a clinical drug pipeline.